检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:吴晓明[1] 李宁[1] 朱继庆[1] 吴艳芳[1] 杜亦陶[1] 迟.依荷巴丽 孙力[3] 杨文芳[4] 黄镜[2] 王志强[4]
机构地区:[1]中国医学科学院北京协和医学院肿瘤医院综合科,北京100021 [2]中国医学科学院北京协和医学院肿瘤医院内科,100021 [3]中国医学科学院北京协和医学院肿瘤医院妇瘤科,100021 [4]中国医学科学院北京协和医学院肿瘤医院麻醉科,100021
出 处:《临床肿瘤学杂志》2011年第1期58-60,共3页Chinese Clinical Oncology
基 金:北京希望马拉松专项基金资助项目(LC2006B23)
摘 要:目的探讨晚期癌痛应用阿片类药物的合理用药方案。方法选择伴有中、重度疼痛的晚期肿瘤患者,分3组,第一组36例,采用盐酸羟考酮控释片(奥施康定)单药治疗;第二组19例,用奥施康定和甲强龙联合治疗;第三组25例,用奥施康定联合加巴喷丁。观察3组患者治疗后的疼痛缓解情况和生活质量。结果单用奥施康定组完全缓解率为63.9%,奥施康定联合甲强龙组为68.4%,奥施康定和加巴喷丁联用组为48.0%。主要毒副反应为便秘,其次为恶心、呕吐。第二组毒副反应最轻,第三组部分患者出现头晕和嗜睡。结论阿片类药物奥施康定治疗晚期癌痛具有较好的疗效,其中奥施康定联合甲强龙尤其适合肺癌伴脑转移或骨转移患者,且安全性高,值得临床推广。Objective The study was to explore rational administration of antalgesic drugs for relieving pain, reducing sideeffects and ameliorating the quality of life (QOL) in patients with advanced cancer. Methods Patients with moderate and severe pain were selected and classified into three groups: administrating oxycodone hydrochloride controlled-release tablets (oxycodone) , oxycodo- ne plus methylprednisolone, oxycodone plus gabapentin, respectively. Pain remission and the quality of life(QOL) in patients were re- corded and compared. Results The rates of complete remission(CR) were 63.9% , 68.4% and 48.0% for the three groups. The ma- jor side-effects were constipation, followed by nausea or vomiting. The second group presented the weakest side-effects, and a minority of patients in the third group appeared somnolence symptoms. Conclusion Opioid drug oxycodone has well efficacy and safety in the treatment of advanced patients with cancer pain, and oxycodone plus methylprednisolone may be the optimal administration of antalgesic drugs for some of the patients with advanced tumors, especially for the lung cancer with brain metastasis and bone metastasis.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.4